1374639-75-4 Usage
Description
LEE011 (succinate) is a potent and selective CDK4/6 inhibitor with oral bioavailability, designed to target and inhibit the activity of cyclin-dependent kinases 4 and 6, which play a crucial role in cell cycle regulation and are often dysregulated in various cancers.
Uses
Used in Pharmaceutical Industry:
LEE011 (succinate) is used as an anti-cancer agent for its ability to inhibit the CDK4/6 proteins, which are commonly overactive in cancer cells. This inhibition can help control the unregulated cell division and growth associated with cancer.
Used in Combination Therapy for Melanoma and Breast Cancer:
In combination with LGX818 (a V600E BRAF specific inhibitor) or BYL719 (a PIK3CA specific inhibitor), LEE011 (succinate) is used to enhance anti-tumor activity in melanoma and breast cancer tumor models. The synergistic effect of these drugs can lead to more robust anti-cancer responses and potentially improve patient outcomes.
Check Digit Verification of cas no
The CAS Registry Mumber 1374639-75-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,7,4,6,3 and 9 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1374639-75:
(9*1)+(8*3)+(7*7)+(6*4)+(5*6)+(4*3)+(3*9)+(2*7)+(1*5)=194
194 % 10 = 4
So 1374639-75-4 is a valid CAS Registry Number.
1374639-75-4Relevant articles and documents
RIBOCICLIB INTERMEDIATE AND PROCESS FOR PREPARATION THEREOF
-
, (2020/06/10)
The present invention relates to the process for the preparation of ribociclib succinate by making use of novel intermediates. The invention also relates to the process for the preparation of novel intermediates.
PREPARATION METHOD OF RIBOCICLIB AND ITS SALT AND CRYSTALLINE FORM THEREOF
-
Paragraph 0044-0045, (2021/02/20)
The present invention provides a preparation method of ribociclib and its salt and a novel crystalline form of ribociclib succinate. The conditions of the preparation method of the present invention are easier than the conventional process, and the yield is higher as well. The purity of ribociclib in crude product stage meets the requirement for quality of active pharmaceutical ingredient (API), so that no further purification is required. The crystalline form of ribociclib succinate in the present invention has outstanding storage stability.
Crystal form of and preparation method and application thereof (by machine translation)
-
Paragraph 0184-0188, (2020/10/14)
The invention relates to a crystal form of, a preparation method and an application thereof. , The invention provides a plurality of novel crystal forms and a preparation method thereof, and the novel crystal forms disclosed by the invention have excellent solubility and the like. (by machine translation)
